title: Rosuvastatin-acenocoumarol interaction.
abstract: BACKGROUND
  Previous evidence suggests that hydroxymethylglutaryl coenzyme A-reductase inhibitors (statins) might potentiate the effect of oral anticoagulants, but a MEDLINE search (key terms: stains, rosuvastatin, anticoagulants, acenocoumarol, and interaction; years: 1980-2005) revealed no reports of an interaction between rosuvastatin and acenocoumarol.
  
  
  OBJECTIVE
  The aim of this article was to describe a case of possible interaction between rosuvastatin and acenocoumarol.
  
  
  METHODS
  We report the case of a 36-year-old male patient receiving long-term oral treatment with acenocoumarol, a synthetic coumarin anticoagulant, who experienced an increase in international normalized ratio (INR) and a hematoma in the left leg approximately 45 days after the initiation of treatment with rosuvastatin.
  
  
  RESULTS
  After discontinuation of both drugs, an unexpectedly rapid decrease in INR was observed.
  
  
  CONCLUSIONS
  Based on the results of this case, a possible pharmacologic interaction between rosuvastatin and acenocoumarol should be considered. Rosuvastatin might enhance the anticoagulant effect of acenocoumarol, and a rebound effect in cases of simultaneous discontinuation of both drugs might occur. Rosuvastatin should be administered with extreme caution in patients receiving long-term acenocoumarol therapy.
authors.affiliation: Division of Cardiology, University of Siena, Italy. mondillo@unisi.it
authors.forename: Sergio
authors.initials: S
authors.lastname: Mondillo
authors.forename: Piercarlo
authors.initials: P
authors.lastname: Ballo
authors.forename: Maurizio
authors.initials: M
authors.lastname: Galderisi
mesh_terms: D000074:Acenocoumarol / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D000284:Administration, Oral; D000328:Adult; D000925:Anticoagulants / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D004347:Drug Interactions; D004359:Drug Therapy, Combination; D005464:Fluorobenzenes / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D006406:Hematoma / Q000139:chemically induced; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D019934:International Normalized Ratio; D007866:Leg; D008297:Male; D011743:Pyrimidines / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D000068718:Rosuvastatin Calcium; D013449:Sulfonamides / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D000925:Anticoagulants; D005464:Fluorobenzenes; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D011743:Pyrimidines; D013449:Sulfonamides; D000068718:Rosuvastatin Calcium; D000074:Acenocoumarol